PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Meta-analysis of 42 RCTs showed that Chai Hu Shu Gan San was more effective than regular Western medicine alone for treating depression [PMID:29454341].
Xiao-Chai-Hu decoction (XCHD) has shown promise in treating hepatitis, inhibiting liver fibrosis, and serving as adjunct therapy for hepatic carcinoma [PMID:40347886].
A placebo-controlled trial indicated that Xiao-Chai-Hu-Tang (XCHT) ameliorates tumor growth in cancer patients with depressive symptoms [PMID:34111616].
Xiao Chai Hu Tang is used to decrease discomfort and virus replication, though rigorous review methodology is required to establish benefits and harms [PMID:31697415].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 10675182 (2000) — Herb-drug interactions. · Lancet (London, England)
- 2.PMID: 34111616 (2021) — Xiao-Chai-Hu-Tang ameliorates tumor growth in cancer comorbid depressive symptoms via modulating gut microbiota-mediated TLR4/MyD88/NF-κB signaling pathway. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 3.PMID: 37277081 (2023) — Saikosaponin B2 ameliorates depression-induced microglia activation by inhibiting ferroptosis-mediated neuroinflammation and ER stress. · Journal of ethnopharmacology
- 4.PMID: 37002971 (2023) — Saikosaponin A and D attenuate skeletal muscle atrophy in chronic kidney disease by reducing oxidative stress through activation of PI3K/AKT/Nrf2 pathway. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 5.PMID: 39981856